Top Pharma Funds Surge: HDFC Pharma Leads with 28% Returns
By Market Desk
Discover the top 10 pharma and healthcare mutual funds delivering over 20% returns in the past year. HDFC Pharma And Healthcare Fund leads with an impressive 28.66% growth.
Ten pharma and healthcare mutual funds delivered over 20% returns in the past year, with HDFC Pharma And Healthcare Fund leading the pack at 28.66%. This strong performance, tracked by Value Research data, highlights a significant uptick in the sector.
Leading Funds Showcase Robust Growth
The top performers within the pharma and healthcare mutual fund category demonstrated substantial gains over the one-year period. Several funds surpassed the 20% return threshold, indicating broad strength.
- HDFC Pharma And Healthcare Fund: 28.66%
- Kotak Healthcare Fund: 28.47%
- PGIM India Healthcare Fund: 27.17%
- Quant Healthcare Fund: 25.64%
- Bajaj Finserv Healthcare Fund: 25.28%
- SBI Healthcare Opportunities Fund: 23.03%
- Mirae Asset Healthcare Fund: 22.39%
- WhiteOak Capital Pharma and Healthcare Fund, Aditya Birla Sun Life Pharma & Healthcare Fund, and UTI Healthcare Fund also surpassed the 20% return mark.
Value Research identifies the broader Pharma category as very high risk. It is recommended for investors seeking a small, supplementary allocation to the sector, provided they can tolerate significant market fluctuations.
Largest Funds Show Mixed Returns
Performance among the largest funds by assets under management presented a varied picture, with top performers not necessarily being the largest in terms of net assets.
- Nippon India Pharma Fund (₹9,279 crore net assets): returned 14.06%
- ICICI Prudential Healthcare Fund (₹6,803 crore in assets): returned 10.94%
This indicates a notable performance gap between these larger schemes and the leading funds mentioned earlier, despite the overall strong sectoral trend. Investors should consider sectoral concentration in their portfolios.